Bullous Pemphigoid Clinical Trial
— PRURIPBOfficial title:
Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid
| Verified date | January 2019 |
| Source | University Hospital, Brest |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Whereas pruritus is a major symptom in bullous pemphigoid, its characteristics and its impact
on quality of life have been little studied.
The objective of this study is to learn more about pruritus characteristics of patients with
bullous pemphigoid, and in consequence to better understand the pathophysiology of pruritus,
and then to better treat pruritus in this condition.
| Status | Completed |
| Enrollment | 63 |
| Est. completion date | October 3, 2018 |
| Est. primary completion date | October 3, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - adult - pruriginous bullous pemphigoid lately diagnosed. - Without PB treatment - MMS (Mini Mental State Examination) = 21 - In hospitalization or consultation Exclusion Criteria: - pregnant woman - nursing women |
| Country | Name | City | State |
|---|---|---|---|
| France | CH Argenteuil | Argenteuil | |
| France | AP-HP, Hôpital Avicenne | Bobigny | |
| France | CHU de Bordeaux | Bordeaux | |
| France | CHRU de Brest | Brest | |
| France | CHU Caen | Caen | |
| France | CHU de Clermont-Ferrand | Clermont-Ferrand | |
| France | AP-HP, Hôpital Henri Mondor | Créteil | |
| France | CHU Le Havre | Le Havre | |
| France | HP-HM | Marseille | |
| France | CHU de Montpellier | Montpellier | |
| France | CH de Niort | Niort | |
| France | AP-HP, Hôpital Bichat | Paris | |
| France | AP-HP, Hôpital Cochin | Paris | |
| France | CHU de Reims | Reims | |
| France | CHU de Rouen | Rouen | |
| France | CHU de Saint-Etienne | Saint-Étienne |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Brest |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Clinical characteristics of pruritus in patients with bullous pemphigoid | Answers and scores in questionnaire about clinical characteristics of pruritus Demographics characteristics of patients Characteristics of the bullous pemphigoid | Day1 ( when diagnosis of bullous pemphigoid is made) | |
| Secondary | Impact of pruritus on quality of life in patients with bullous pemphigoid | Score 5D itch scale | Day 1 (when diagnosis of bullous pemphigoid is made ) | |
| Secondary | Impact of pruritus on quality of life in patients with bullous pemphigoid | score ItchyQol (Itchy Quality of Life) | Day1 (when diagnosis of bullous pemphigoid is made ) | |
| Secondary | Impact of pruritus on quality of life in patients with bullous pemphigoid | score ABQOL | Day 1 (when diagnosis of bullous pemphigoid is made ) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03286582 -
A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid
|
Phase 2 | |
| Completed |
NCT02837965 -
Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid
|
||
| Recruiting |
NCT03636763 -
Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?
|
||
| Recruiting |
NCT00802243 -
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
|
Phase 2 | |
| Completed |
NCT05649579 -
Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
|
||
| Active, not recruiting |
NCT04206553 -
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
|
Phase 2/Phase 3 | |
| Completed |
NCT00431119 -
Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid
|
Phase 2 | |
| Completed |
NCT04563923 -
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
|
Phase 2 | |
| Completed |
NCT03320798 -
Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients
|
N/A | |
| Completed |
NCT02883894 -
Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid
|
N/A | |
| Completed |
NCT00809822 -
Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.
|
Phase 2 | |
| Recruiting |
NCT05594472 -
Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
|
Phase 3 | |
| Withdrawn |
NCT05061771 -
Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
|
Phase 3 | |
| Not yet recruiting |
NCT04128176 -
Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
|
Phase 3 | |
| Recruiting |
NCT05284929 -
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
|
||
| Terminated |
NCT04612790 -
A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.
|
Phase 3 | |
| Recruiting |
NCT05681481 -
A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
|
Phase 3 | |
| Completed |
NCT00286325 -
Rituximab in the Treatment of Patients With Bullous Pemphigoid
|
Phase 1/Phase 2 | |
| Completed |
NCT04728854 -
Telederm and Bullous Pemphigoid
|
||
| Completed |
NCT04117932 -
Efficacy and Safety of Ustekinumab in Bullous Pemphigoid
|
Phase 2 |